drugset
drugset / Trial / NCT05970887

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

NCT05970887 ↗

Phase 4 Completed 154 enrolled Catholic Kwandong University Korea University Guro Hospital · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The goal is to evaluate the immunogenicity and safety of coadministration of a bivalent BA.4/BA.5-adapted COVID-19 booster vaccine, and influenza vaccine among healthy adults during 2022-23 season.

Timeline

Start
2022-10-12
Primary completion
2022-12-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BNT162b2 Messenger RNA (mRNA) 15 ug —
Subject Quadrivalent influenza vaccine Vaccine 15 ug —
Subject Quadrivalent influenza vaccine Vaccine 0.5 ml —

Indications

No indication recorded.